220 related articles for article (PubMed ID: 25309827)
1. Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.
Shan L; Liu Y; Wang P
J Basic Clin Med; 2013; 2(2):1-6. PubMed ID: 25309827
[TBL] [Abstract][Full Text] [Related]
2. Immunotoxin treatment of cancer.
Pastan I; Hassan R; FitzGerald DJ; Kreitman RJ
Annu Rev Med; 2007; 58():221-37. PubMed ID: 17059365
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.
Zhu S; Liu Y; Wang PC; Gu X; Shan L
Biomed Res Int; 2017; 2017():7929286. PubMed ID: 28752098
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxins and nanobody-based immunotoxins: review and update.
Khirehgesh MR; Sharifi J; Safari F; Akbari B
J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
[TBL] [Abstract][Full Text] [Related]
5. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
6. Anti-cancer Immunotoxins, Challenges, and Approaches.
Dashtiahangar M; Rahbarnia L; Farajnia S; Salmaninejad A; Shabgah AG; Ghasemali S
Curr Pharm Des; 2021; 27(7):932-941. PubMed ID: 33023437
[TBL] [Abstract][Full Text] [Related]
7. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin.
Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS
BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895
[TBL] [Abstract][Full Text] [Related]
10. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
Mathew M; Verma RS
Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
[TBL] [Abstract][Full Text] [Related]
11. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
[TBL] [Abstract][Full Text] [Related]
12. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
Mazor Y; Noy R; Wels WS; Benhar I
Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
[TBL] [Abstract][Full Text] [Related]
13. Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH.
Liu X; Tan Q; Wen J; Wang X; Yang G; Li Y; Lu M; Ye W; Si A; Ma S; Ding T; Sun L; Liu F; Zhang M; Jiang T; Gao W
J Transl Med; 2023 Aug; 21(1):572. PubMed ID: 37626430
[TBL] [Abstract][Full Text] [Related]
14. Immunotoxin: A new tool for cancer therapy.
Allahyari H; Heidari S; Ghamgosha M; Saffarian P; Amani J
Tumour Biol; 2017 Feb; 39(2):1010428317692226. PubMed ID: 28218037
[TBL] [Abstract][Full Text] [Related]
15. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
Wenning LA; Murphy RM
Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
[TBL] [Abstract][Full Text] [Related]
16. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
Tsutsumi Y; Onda M; Nagata S; Lee B; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8548-53. PubMed ID: 10890891
[TBL] [Abstract][Full Text] [Related]
17. Reduction of non-specific toxicity of immunotoxin by intein mediated reconstitution on target cells.
Wang J; Han L; Chen J; Xie Y; Jiang H; Zhu J
Int Immunopharmacol; 2019 Jan; 66():288-295. PubMed ID: 30502650
[TBL] [Abstract][Full Text] [Related]
18. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
19. Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins.
Niv R; Cohen CJ; Denkberg G; Segal D; Reiter Y
Curr Pharm Biotechnol; 2001 Mar; 2(1):19-46. PubMed ID: 11482347
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
